AMAG AMAG Pharmaceuticals, Inc. featured news, full reports, and detailed charts
AMAG Pharmaceuticals, Inc. (AMAG) Wrap Up:
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States and internationally. The company also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Ferumoxytol, an iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients; Feridex I.V., a liver contrast agent; and GastroMARK, an oral contrast agent for delineating the bowel in MRI. The company’s products also include Combidex, an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use wit...AMAG Pharmaceuticals, Inc. (AMAG:NASDAQ)
Snapshot of AMAG Pharmaceuticals, Inc. (AMAG)
|
OPEN
--
|
PREVIOUS CLOSE
$39.81
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
07/1/09 - $58.23
|
52 WEEK LOW
03/3/09 - $22.20
|
|
|
MARKET CAP
682.1M
|
AVERAGE VOLUME 3 mo
550.4K
|
|
|
DILUTED EPS TTM
$-5.67
|
SHARES OUTSTANDING
17.1M
|
|
|
AMAG Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
What Wall Street analysts are saying about selected stocks in the news Friday
AMAG Top Compensated Officers
Executives, Board Directors
Key developments for AMAG Pharmaceuticals, Inc. (AMAG)
AMAG Pharmaceuticals Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. Total revenues for the quarter ended September 30, 2009 were $3.0 million as compared to total revenues of $0.3 million for the same period in 2008. The company reported a net loss of $22.1 million, or a loss of $1.29 per basic and diluted share, for the quarter ended September 30, 2009, as compared to a net loss of $23.6 million, or a loss of $1.39 per basic and diluted share, for the same period in 2008. Operating loss was $22.6 million against $24.6 million a year ago. Net loss before income taxes was $22.1 million against $23.9 million a year ago. Total revenues for the nine month period ended September 30, 2009 were $4.0 million as compared to $1.4 million for the same period in 2008. Net loss for the nine months ended September 30, 2009 was $74.9 million, or a loss of $4.39 per basic and diluted share, as compared to a net loss of $49.9 million, or a loss of $2.94 per basic and diluted share for the same period in 2008. Operating loss was $77.8 million against $56.4 million a year ago. Net loss before income taxes was $75.1 million against $50.2 million a year ago.
AMAG Pharmaceuticals, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on October 28, 2009).
AMAG Pharmaceuticals, Inc., Q3 2009 Earnings Call, Oct 29 2009
AMAG Competitors
| Company | Last | Change |
| Rockwell Medical Technologies Inc | $6.39 USD | -0.01 |
| Watson Pharmaceuticals Inc | $35.53 USD | -0.34 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | AMAG | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 147.8x |
|
| Price/Book | 4.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 125.9x |
|
|
AMAG |
||
AMAG transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||